BA 1105
Alternative Names: BA-1105; Claudin 18.2 (ADCC) - Shandong Boan BiotechnologyLatest Information Update: 02 Feb 2022
At a glance
- Originator Shandong Boan Biotechnology
- Developer Luye Pharma Group; Shandong Boan Biotechnology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gastric cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 26 Jan 2022 Phase-I clinical trials in Solid tumours in China (Parenteral (9348109)
- 26 Jan 2022 Luye Pharma initiates a phase I for Solid tumors in China
- 16 Oct 2021 Phase-I clinical trials in Gastric cancer (Late-stage disease) in China (Parenteral) before October 2021 (Shandong Boan Biotechnology pipeline, October 2021)